News Perspective Therapeutics, Inc.

Stocks

CATX

US46489V3024

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 15:16:10 18/08/2026 BST			5-day change	1st Jan Change
3.165 ^USD	-1.71%		+0.79%	+16.55%

08-14	BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6	MT
08-11	Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says	MT

All News

Mentions Relevance

08-14	BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6	MT
08-11	Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says	MT
08-10	Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results	AQ
08-10	Perspective Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-31	Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results	AQ
07-28	Perspective Therapeutics' Neuroendocrine Tumor Therapy Receives EU Orphan Drug Designation	MT
07-28	Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs	AQ
07-17	Perspective Therapeutics Data On 212Pb VMT-a-NET Accepted For Oral Presentation At ESMO Congress 2026	CI
07-17	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026	AQ
07-08	Perspective Therapeutics, Inc. Announces Executive Changes	CI
07-08	Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-Founder Michael Schultz Moves to Advisory Role	MT
07-08	Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor	AQ
06-03	Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort	MT
06-03	Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study	AQ
06-03	Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study	CI
05-21	Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma	AQ
05-18	Perspective Therapeutics, Inc. Announces First Patients Dosed In New Cohorts Of Ongoing Phase 1/2a Studies	CI
05-18	Perspective Therapeutics Doses First Patients for New Cohorts of Two Phase 1/2a Studies in Tumors	MT
05-18	Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies	AQ
05-14	Perspective Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 02:20 PM
05-11	Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-11	Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results	AQ
05-10	Perspective Therapeutics, Inc. - Shareholder/Analyst Call
04-24	Perspective Therapeutics to Provide Several Upcoming Corporate Updates	AQ
04-20	Perspective Therapeutics Provides Updated Interim Results From Phase 1/2a Cancer Trial	MT